Two-year real-world data highlight strong drug survival and effectiveness of bimekizumab in plaque psoriasis. Learn more ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

Arcutis Biotherapeutics and Kowa Pharmaceuticals are cutting ties on their U.S. marketing partnership around Arcutis’ Zoryve ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, ...

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Johnson & Johnson projects $100 billion in annual sales, driven by growth in blockbuster cancer drugs like Darzalex and the launch of a new psoriasis treatment.

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved a wide range of recombinant DNA (r-DNA)-origin drugs and biologics for manufacture ...

Many treatments exist, but choosing Ayurveda may be the best option because it aims to address the root cause, uses natural herbal remedies, and focuses on long-term relief. Psoriasis is a ...

GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

Moderate to severe PPP can be effectively and safely treated with apremilast through 52 weeks, with improvement seen as early as week 2.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

In over a decade of building saunas at SaunaCloud, I’ve noticed a pattern: people spend thousands on 'miracle' creams ...